Vaishali Pharma Limited Releases Unaudited Financial Results for Q1 FY2026; Approves AGM Details
Vaishali Pharma Limited has announced the outcomes of its Board meeting held on August 14, 2026. The company released its unaudited financial results and approved key operational matters ahead of its upcoming general body meeting.The Board meeting considered and approved several items, including the unaudited financial results for the first quarter ended June 30, 2026, alongside the Limited Review Report prepared by the statutory auditor. Additionally, the company's Annual Report and Director's Report for the Financial Year 2025-26 were reviewed.
Key decisions approved during the Board meeting included setting up the 19th Annual General Meeting (AGM), which is scheduled to be held on Thursday, September 24, 2026, via Video Conferencing or other Audio-Visual Means. The Register of Members and Share transfer books will be closed from Friday, September 18, 2026, to Thursday, September 24, 2026, for the purpose of the AGM. HD & Associates, Company Secretaries, were also appointed as a Scrutinizer to conduct remote e-voting for the AGM.
Standalone Financial Results Summary
The statutory auditors conducted a limited review of Vaishali Pharma Limited's unaudited standalone financial results for the quarter ended June 30, 2026. The company remains engaged in the sale of pharmaceutical products within a single business segment.Financial performance indicators from the unaudited standalone statement are detailed below:
| Particulars | Quarter Ended June 30, 2026 (Amt in Lacs) |
|---|---|
| Total Income (I + II) | 2,818.91 |
| Total Expenses | 2,800.97 |
| Profit Before Tax | 17.94 |
| Net Profit for the Quarter | 26,64,182 |
Consolidated Financial Results
The company also released its unaudited consolidated financial results for the quarter ended June 30, 2026, which includes the share of profit from its associate company, Kesar Pharma Limited. Vaishali Pharma acquired a stake in Kesar Pharma Limited on September 10, 2025.The consolidated statement shows robust income generation:
| Particulars | Quarter Ended June 30, 2026 (Amt in Lacs) |
|---|---|
| Total Income (I + II) | 11,260.76 |
| Total Expenses | 10,722.07 |
| Profit Before Tax | 538.69 |
| Net Profit for the Quarter | 4,03,16,670 |
The company's management is responsible for preparing these statements in accordance with Indian Accounting Standards (Ind AS). The consolidated results reflect that the company has a significant investment in its domestic associate, whose financial results show a net profit after tax of Rs. 5.65 Lakh.
VAISHALI Stock Price Movement
Shares of Vaishali Pharma Limited finished the day lower, slipping 0.35% to settle at ₹8.44 in today’s trading session. The stock registered a traded volume of 116,620 shares during the close.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.